Bleeding [patf]
Pattern [spco]
Endometrial [spco]
Continuous [idcn]
Combined [qlco]
Hormone replacement therapy [topp]
Objective [inpr]
establish [qlco]
Optimum [qlco]
Oral [spco]
Daily Dose [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
GIVEN [cnce]
Combination [qlco]
Fixed [fndg]
Oral [spco]
Dose [qnco]
Estrone [horm, phsu, strd]
Sulfate [inch]
Hormone replacement therapy [topp]
Endometrial [spco]
Protection [fndg]
Cessation [acty]
Vaginal Bleeding [patf]
Methods [inpr]
randomized [resa]
Double-Blind Study [resa]
Conduct [inbe]
Five [qnco]
Eight [qnco]
postmenopausal [tmco]
Women [popg]
randomized [resa]
Take [hlca]
Sulfate [inch]
mg% [qnco]
Daily [tmco]
Doses [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
2 5 [qnco]
mg% [qnco]
Daily [tmco]
Vaginal Bleeding [patf]
Record [inpr]
Patients [podg]
Daily [tmco]
diary [inpr]
endometrial biopsy [diap]
Performed [ftcn]
Entry [inpr]
Study [mnob]
months [tmco]
Percent [qnco]
Women [popg]
Reported [inpr]
Bleeding [patf]
therapy [ftcn]
Women [popg]
2 5 [qnco]
mg% [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
Group [idcn]
Percentage [qnco]
Women [popg]
Bleeding [patf]
Increased [qnco]
Group [idcn]
months [tmco]
2 5 [qnco]
mg% [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
Group [idcn]
Approximately [qlco]
Women [popg]
Continue [idcn]
Bleeding [patf]
Dose [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
statistically significant [qnco]
Women [popg]
Bleeding [patf]
Time Point [tmco]
Group [idcn]
Cases [ftcn]
Endometrial Hyperplasia [dsyn]
Reported [inpr]
Study Population [popg]
Doses [qnco]
medroxyprogesterone acetate [horm, phsu, strd]
GIVEN [cnce]
Combination [qlco]
mg% [qnco]
Sulfate [inch]
Adequate [qlco]
Endometrial [spco]
Protection [fndg]
Approximately [qlco]
Women [popg]
months [tmco]
therapy [ftcn]
